Mark Fabian

Tredje AP-fonden (AP3) is the Swedish government-owned pension fund management firm which was founded in 2001 to act as a buffer by using their capital to fund future pension payments and to generate investment returns to finance the Swedish pension system. Headquartered in Stockholm, AP3 is mandated by Parliament and regulated by the Swedish National Pension Funds Act to generate maximum possible benefit for the pension system by managing their fund capital to deliver strong investment returns at low risk.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden.

Skandinaviska Enskilda Banken AB (Broker) (SEB-Broker) is the broker/dealer division of Skandinaviska Enskilda Banken AB (STO: SEB-A; OTCMKTS: SVKEF), a financial group headquartered in Stockholm, Sweden. Founded in 1856, SEB-Broker provides trading and executions services to their clients.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.

KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.

Biothea Pharma, Inc. is an American biotechnology company that operates in the field of pharmaceuticals. The private company was founded by John F. Vavricka. Marina S. Bozilenko has been the CEO of the company since 2021.

Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million.